Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib in recurrent ovarian, peritoneal, or fallopian tube cancer
NCT00275028Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2005
- Primary completion
- Mar 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cediranib in ovarian cancer, primary peritoneal serous adenocarcinoma (PPSC), fallopian tube cancer (PFTC), sponsored by National Cancer Institute. Started Oct 2005; status: completed.
02
Drugs
cediranib
03
Conditions
ovarian cancerprimary peritoneal serous adenocarcinoma (PPSC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT00275028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00275028.